Marker Therapeutics (MRKR) to Release Quarterly Earnings on Thursday

Marker Therapeutics (NASDAQ:MRKR) is projected to post its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect Marker Therapeutics to post earnings of ($0.69) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 20, 2025 at 7:00 AM ET.

Marker Therapeutics (NASDAQ:MRKR) last announced its earnings results on Thursday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.26. Marker Therapeutics had a negative return on equity of 114.59% and a negative net margin of 271.12%.The company had revenue of $0.86 million during the quarter, compared to analyst estimates of $0.72 million. On average, analysts expect Marker Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Marker Therapeutics Trading Down 3.9%

Shares of NASDAQ MRKR opened at $0.93 on Wednesday. Marker Therapeutics has a 1-year low of $0.81 and a 1-year high of $5.95. The company has a 50-day moving average of $0.96 and a two-hundred day moving average of $1.22. The company has a market cap of $12.06 million, a PE ratio of -0.68 and a beta of 1.47.

Institutional Trading of Marker Therapeutics

An institutional investor recently bought a new position in Marker Therapeutics stock. Jane Street Group LLC bought a new stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 21,800 shares of the company’s stock, valued at approximately $33,000. Jane Street Group LLC owned 0.19% of Marker Therapeutics at the end of the most recent reporting period. Institutional investors own 22.39% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on MRKR shares. Wall Street Zen raised Marker Therapeutics to a “sell” rating in a research report on Saturday, August 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $10.25.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.